Your browser doesn't support javascript.
loading
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.
DiScala, Molly; Najor, Matthew S; Yung, Timothy; Morgan, Deri; Abukhdeir, Abde M; Cobleigh, Melody A.
Afiliación
  • DiScala M; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
  • Najor MS; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
  • Yung T; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
  • Morgan D; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Missouri, United States of America.
  • Abukhdeir AM; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
  • Cobleigh MA; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
PLoS One ; 15(6): e0234146, 2020.
Article en En | MEDLINE | ID: mdl-32525891
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Resistencia a Antineoplásicos / Factor de Transcripción STAT6 / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Resistencia a Antineoplásicos / Factor de Transcripción STAT6 / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos